Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study
Ospemifene was shown to be effective and well tolerated for the treatment of the symptoms of vaginal dryness and dyspareunia associated with vulvovaginal atrophy over and above the use of provided lubricants. Expand
Phenotypic characterization of human decidual macrophages
- J. Heikkinen, M. Möttönen, J. Komi, A. Alanen, O. Lassila
- Biology, Medicine
- Clinical and experimental immunology
- 1 March 2003
The findings suggest that decidual macrophages could represent an inhibitory type of APCs at the maternal–fetal interface, and indoleamine 2,3‐dioxygenase (IDO), suggested to have an immunosuppressive role in pregnancy, was expressed in decidUAL macrophage. Expand
Prevalence and impact of vaginal symptoms among postmenopausal women.
The prevalence and perceived severity of VVA symptoms were substantial but less frequent in nonsexually active women and analysis of MHT use by past or current hormone use indicated a trend away from oral dosing and towards patch or vaginal hormones. Expand
Effects of ospemifene, a novel SERM, on hormones, genital tract, climacteric symptoms, and quality of life in postmenopausal women: a double-blind, randomized trial
- E. Rutanen, J. Heikkinen, K. Halonen, J. Komi, R. Lammintausta, O. Ylikorkala
- 1 September 2003
Ospemifene at daily doses of 30 to 90 mg did not stimulate endometrium or aggravate hot flashes but clearly had a rather strong estrogenic effect on the vaginal epithelium during a 3-month treatment period, as evidenced by an increase in intermediate and superficial cells in repeat Pap smears. Expand
Nonsteroidal anti-estrogens inhibit the functional differentiation of human monocyte-derived dendritic cells.
Results of this study show that the nonsteroidal anti-estrogens toremifene and tamoxifen inhibit this differentiation of dendritic cells and may have a role in the treatment and prevention of autoimmune diseases. Expand
Effects of ospemifene and raloxifene on hormonal status, lipids, genital tract, and tolerability in postmenopausal women
Ospemifene, at the dose of 90 mg/day, was more estrogenic than raloxifenes, as shown by changes in serum follicle-stimulating hormone and sex hormone-binding globulin levels. Expand
Effects of ospemifene, a novel SERM, on vascular markers and function in healthy, postmenopausal women
Neutral effects of short-term use of ospemifene on vascular surrogate markers imply no effect for oSpemifenes on the risk for cardiovascular disorders in healthy, postmenopausal women. Expand
Effects of ospemifene, a novel SERM, on biochemical markers of bone turnover in healthy postmenopausal women
- J. Komi, J. Heikkinen, M. Rutanen, K. Halonen, R. Lammintausta, O. Ylikorkala
- Gynecological endocrinology : the official…
- 1 January 2004
The results show that ospemifene is effective in reducing bone turnover in postmenopausal women. Expand
Effects of ospemifene (FC-1271a) on uterine endometrium, vaginal maturation index, and hormonal status in healthy postmenopausal women.
- S. Voipio, J. Komi, L. Kangas, K. Halonen, M. Degregorio, R. Erkkola
- 20 November 2002
The study suggests that a safe and well tolerated dose of ospemifene for potential clinical use may be between 25 and 100 mg, and suggests that the highest dose level (200 mg) induced more subjective adverse reactions, especially hot flushes, than lower doses. Expand
Effects of ospemifene and raloxifene on biochemical markers of bone turnover in postmenopausal women
The study confirms the bone-restoring activity of ospemifene, which is comparable to that of raloxifene. Expand